Spots Global Cancer Trial Database for pharmacokinetic sampling
Every month we try and update this database with for pharmacokinetic sampling cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours | NCT01921140 | Solid Tumours | Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa... | 18 Years - 130 Years | AstraZeneca | |
| To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours | NCT01921140 | Solid Tumours | Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa... | 18 Years - 130 Years | AstraZeneca | |
| To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours | NCT01900028 | Solid Tumours | Pharmacokinetic... Olaparib tablet... Itraconazole | 18 Years - 130 Years | AstraZeneca | |
| Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven | NCT06030089 | Acute Myeloid L... | Pharmacokinetic... Vital status de... Toxicity assess... Venetoclax and ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven | NCT06030089 | Acute Myeloid L... | Pharmacokinetic... Vital status de... Toxicity assess... Venetoclax and ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | NCT01929603 | Solid Tumours | Pharmacokinetic... Rifampicin Olaparib tablet... | 18 Years - 99 Years | AstraZeneca | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours | NCT01921140 | Solid Tumours | Olaparib tablet... Pharmacokinetic... Dietary Fasted Dietary High Fa... | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | NCT02093351 | Solid Tumours | Olaparib Tamoxifen Anastrozole Letrozole Pharmacokinetic... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
